Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3
 in patients with localized prostate cancer.
This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to
 evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate
 cancer.

 Subjects enrolled will be diagnosed with localized prostate cancer (clinical stage T1/T2)
 having a Gleason score of 6 to 7 (3+4 or 4+3). Subjects will receive up to four (4)
 transrectal ultrasound (TRUS)-guided IT treatments with Ad5-SGE-REIC/Dkk-3 into the prostate
 approximately 6-weeks apart. Each treatment cycle will be performed using a minimum of three
 track injections through the prostrate using a total of 3 mL volume. Approximately 2 mL of
 the total volume will be injected into the most dense areas of cancer based on biopsy and MRI
 mapping (fusion biopsy) and 1 mL total volume will be injected into the opposite lobe of the
 prostate or other areas to ensure complete saturation of the prostate over multiple
 injections.

 Subjects who, in the opinion of the investigator, are progressing at any time after the
 second injection of Ad5-SGE-REIC/Dkk-3 may be discontinued and will be treated according to
 standard medical practice.
Inclusion Criteria:

 Key Inclusion Criteria:

 Subjects must meet all of the following criteria to be included:

 1. Male aged between 50 and 80 years (inclusive) with histologically documented
 clinically localized, adenocarcinoma of the prostate.

 2. Subject with clinical stage T1 or T2 with Gleason score of 6 or 7 (3+4 or 4+3).

 3. At least one (1) MRI evaluable tumor with volume of 400 mm3 or greater.

 4. At least total of 10 mm of cancer tissue based on an MRI guided 12-core biopsy.

 5. Recent (≤ 6 months prior to study entry) negative bone scan and computerized
 tomography (CT) scan of abdomen/pelvis.

 6. Life expectancy of at least 5 years.

 7. Subjects should have adequate bone marrow function defined as an absolute peripheral
 granulocyte count ≥ 1,500 and platelet count of ≥ 100,000, adequate hepatic function
 with a bilirubin ≤ 1.5 mg/dl and serum glutamic-pyruvic transaminase (SGPT) < 4x the
 upper limits of normal, adequate renal function defined as serum creatinine ≤ 2.0
 mg/dl

 8. Subjects must have a coagulation profile (prothrombin time [PT], partial
 thromboplastin time [PTT]) not more than 2-times the upper limit of normal and no
 history of substantial non-iatrogenic bleeding diatheses. Use of anticoagulants within
 5-days of the Ad5-SGE-REIC/Dkk-3 injections is limited to local use only (for control
 of central line patency).

 9. Subject is willing to refrain from sexual activity or agrees to use a barrier
 contraceptive device (e.g. condom) for 8-weeks after treatment with
 Ad5-SGE-REIC/Dkk-3.

 10. Subjects must sign an informed consent indicating that they are aware of the
 investigational nature of the study.

 Key Exclusion Criteria

 Subjects meeting any of the following criteria will be excluded:

 1. Prior primary radiation treatment to the prostate.

 2. Severe bladder outlet obstructive disorder (AUA >25) or urinary track retention.

 3. Chemotherapy, immunotherapy or other investigational study drug within the past 4
 weeks.

 4. Unable to tolerate TRUS.

 5. Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric
 disorders, that in the opinion of the investigator put the subject at significant
 risk, are not eligible.

 6. Subjects who are HIV positive or have active hepatitis B or C infections are not
 eligible.

 7. Subjects with a clinical history of primary or secondary immunodeficiency, autoimmune
 disease or subjects taking immunosuppressive drugs such as corticosteroids
 continuously for > 4 months [> 5 mg hydrocortisone/day] are ineligible.

 8. As a result of medical review, physical examination, the Principal Investigator (or
 medically qualified nominee) considers the subject unfit for the study.